Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658284 | PMC |
| http://dx.doi.org/10.1016/j.ekir.2023.08.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A rare case of dual glomerular pathology: Alport syndrome and immune complex-mediated MPGN.
BMC Nephrol
September 2025
Cerrahpasa Medical Faculty, Division of Nephrology, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Background: Immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) and Alport syndrome are distinct glomerular diseases with different pathophysiologic mechanisms. Their coexistence is extremely rare and may present diagnostic and therapeutic challenges.
Case Presentation: A 42-year-old woman presented with persistent proteinuria and hematuria.
An Unusual Case of Membranoproliferative Glomerulonephritis: Is the Role of Vaccination in Immune Reactivation a Casual or Causal Effect?
Reports (MDPI)
August 2025
Department of Nephrology, Hospital Central Defense Gomez Ulla, 28047 Madrid, Spain.
Membranoproliferative glomerulonephritis (MPGN) is a rare and heterogeneous pattern of immune-mediated glomerular injury, often associated with infections, autoimmune disorders, or monoclonal gammopathies. Idiopathic cases remain a diagnostic challenge and frequently require empirical immunosuppressive treatment. There is increasing interest in environmental triggers that may activate the immune system in genetically or immunologically predisposed individuals.
View Article and Find Full Text PDFRare presentation of hypocomplementaemic urticarial vasculitis syndrome (HUVS) overlapping with systemic erythematosus lupus (SLE) and small lymphocytic lymphoma (SLL).
BMJ Case Rep
February 2025
Rheumatology, Montefiore Medical Center, New York, New York, USA.
Hypocomplementaemic urticarial vasculitis syndrome (HUVS) is a rare immune complex-mediated disorder marked by non-pruritic urticarial lesions, hypocomplementaemia (low C1q levels), leucocytoclastic vasculitis and systemic manifestations (joint pain, angio-oedema and uveitis). Complications include renal disease, lung disease and acute laryngeal oedema that can prove fatal. Distinguishing HUVS from systemic lupus erythematosus (SLE) is challenging due to overlapping symptoms and diagnostic criteria.
View Article and Find Full Text PDFUnusual Cases of Monoclonal Gammopathy of Renal Significance.
Case Rep Nephrol
September 2024
Department of Pathology CIUSSS de la Mauricie-et-du-Centre-du-Québec, Trois-Rivières, Canada.
Article Synopsis
- Monoclonal gammopathy of renal significance (MGRS) is characterized by kidney issues linked to abnormal immunoglobulin production, found in patients without specific treatment criteria for hematological diseases.
- The three cases discussed include a patient with chronic lymphocytic leukemia and monoclonal membranoproliferative glomerulonephritis, a second patient with IgM MGUS presenting renal thrombotic microangiopathy, and a third with immunotactoid glomerulonephritis likely due to small B-cell lymphoma.
- Each case highlights unique renal complications tied to the presence of monoclonal proteins and emphasizes the challenges in diagnosis and management of MGRS in different
STAT3 inhibition ameliorates renal interstitial inflammation in MRL/lpr mice with diffuse proliferative lupus nephritis.
Ren Fail
December 2024
Department of Nephrology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Article Synopsis
- Acute kidney injury (AKI) is a serious complication of diffuse proliferative lupus nephritis (DPLN) that worsens renal function, but effective treatments and understanding of its mechanisms are still needed.
- Research showed a significant link between interstitial leukocytes and AKI in DPLN patients, while experiments on MRL/lpr mice indicated that blocking the STAT3 signaling pathway can reduce kidney damage.
- The study suggests that targeting STAT3 through a combination of FLLL32 and methylprednisolone could be a promising new treatment approach for DPLN patients suffering from AKI.